The first time a procurement director asked us where our polymer's raw materials come from. Not where the polymer itself is manufactured. Where the inputs came from. We paid attention. That question had not come up the previous year. It came up four times the year after.

Something had shifted in how regulated-market buyers were thinking about their excipient supply chains. Not in the way supply chain disruption is usually described: shortages, delays, freight costs. Those are recoverable. What shifted was the underlying question about concentration risk. About what happens if a single geography becomes inaccessible. Not for weeks. For months, or longer.

Excipients have always sat at the quieter end of pharmaceutical supply chain scrutiny. APIs get the dual-source requirements, the regulatory monitoring, the senior attention. Excipients are assumed available, assumed substitutable. That assumption has been wrong for years. The last five years made it difficult to ignore.

A coating polymer disruption stops a tablet line as completely as an API shortage. The difference is that qualifying a replacement polymer in a modified release product takes six to twelve months under normal regulatory timelines. There is no expedited route for that. The only way to manage the risk is to have started qualification before the disruption.

What we are hearing from buyers in regulated markets now is different from what we heard in 2019. Country of origin was a checkbox. Today it is a conversation. Buyers want to know not just where the excipient is manufactured but where the inputs come from. A polymer manufactured in India from Chinese-origin monomers carries a different risk profile than one built entirely from local inputs. Buyers who understand their supply chains are asking that distinction.

The shift toward India as a sourcing destination is not new. What is new is that excipients are now part of that conversation. India manufactures approximately 40% of generics approved in the United States. The regulatory infrastructure is deep and long-established: WHO cGMP, US FDA inspection readiness, ICH-compliant quality systems built over decades. What is different now is that procurement teams are looking at excipient suppliers through the same lens they have been using for API suppliers for years.

We are India's first EXCiPACT GMP-certified polymer excipient manufacturer. That certification has been in place since 2015. Not something obtained in response to supply chain conversations. Something that has survived multiple audit cycles across a period that included the most disruptive years in recent pharmaceutical supply chain history. US DMF registration, WHO cGMP compliance and ISO 9001 certification are in place across our DRUGCOAT®, DRCOAT®, APION® and AQUAPOL® ranges.

‍

The buyers who are moving fastest on this are not the ones responding to a disruption. They are the ones running supply chain reviews while their current arrangements are still working. That is the only position from which the qualification timeline is manageable. Six to twelve months for a modified release product is not a crisis response. It is a planning horizon.

The suppliers who hold positions in regulated-market supply chains over the next decade will be the ones whose documentation, certification and manufacturing continuity made qualification manageable for buyers who had options. Not the ones competing on price at the point when a buyer has no time to qualify alternatives.

We established this business in 1985. Today we supply manufacturers across 45+ countries. That span has given us a clear view of how this plays out. The procurement teams who called us before they needed us are in a different position today than the ones who called when they had no choice.

Reviewing Your Excipient Supply Chain? Talk to Us.

If your supply chain review has reached excipient sourcing, we are ready for that conversation. Tell us which markets you supply and what your qualification process requires.

Write to us at contact@vikramthermo.com

‍